Nivolumab-induced aplastic anemia: A case report and literature review

被引:32
作者
Comito, Rachel R. [1 ]
Badu, Lynette A. [1 ]
Forcello, Nicholas [2 ]
机构
[1] Hartford Hosp, Hartford, CT 06115 USA
[2] Yale New Haven, Smilow Canc Hosp, 20 York St, New Haven, CT 06510 USA
关键词
Nivolumab; glioblastoma; aplastic anemia; immune checkpoint; programmed cell death-1 receptor; IMMUNE CHECKPOINT; HEMOLYTIC-ANEMIA; CANCER;
D O I
10.1177/1078155217726159
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Directed immunotherapy at the programmed cell death-1 receptor has demonstrated efficacy in non-small-cell lung cancer, metastatic melanoma, and various other malignancies. Immune checkpoint inhibitors are innovative therapies producing some impressive clinical responses with a more manageable adverse effect profile when compared to traditional chemotherapy. The more common adverse effects associated with these agents include fatigue, rash, myalgia, pyrexia, and cough, but less common yet serious adverse effects have included immune-mediated colitis, pneumonitis, hepatitis, type 1 diabetes, and encephalitis. Here we present a case of a female patient with glioblastoma multiforme, who was treated with the programmed cell death-1 receptor inhibitor nivolumab and subsequently developed aplastic anemia.
引用
收藏
页码:221 / 225
页数:5
相关论文
共 20 条
[1]  
American Brain Tumor Association, 2014, GLIOBL GBM
[2]  
[Anonymous], 2014, OPDIVO NIV PACK INS
[3]  
Bristol-Meyers S, BRISTOL MYERS SQUIBB
[4]  
Food and Drug Administration, GLEOST LOM CAPS
[5]   Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review [J].
Friedman, Claire F. ;
Proverbs-Singh, Tracy A. ;
Postow, Michael A. .
JAMA ONCOLOGY, 2016, 2 (10) :1346-1353
[6]  
Gerson SL, 2011, CANC CHEMOTHERAPY BI
[7]   Immune Checkpoint in Glioblastoma: Promising and Challenging [J].
Huang, Jing ;
Liu, Fangkun ;
Liu, Zhixiong ;
Tang, Hui ;
Wu, Haishan ;
Gong, Qianni ;
Chen, Jindong .
FRONTIERS IN PHARMACOLOGY, 2017, 8
[8]   Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies [J].
Naidoo, J. ;
Page, D. B. ;
Li, B. T. ;
Connell, L. C. ;
Schindler, K. ;
Lacouture, M. E. ;
Postow, M. A. ;
Wolchok, J. D. .
ANNALS OF ONCOLOGY, 2015, 26 (12) :2375-2391
[9]  
National Cancer Institute, 2016, IMM GLIMM PROGR GLIO
[10]  
Omuro A, 2017, NEURO-ONCOLOGY, V19, P13